Please ensure Javascript is enabled for purposes of website accessibility

Can Merck Recover From This FDA Rejection?

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Merck's latest setback comes from the Food and Drug Administration's rejection of sugammadex.

Merck (MRK 1.18%) announced this week that its experimental anesthesia reversal drug sugammadex was rejected by the Food and Drug Administration. This isn't the only drug that the big pharma company has failed to get past the FDA this year; its insomnia drug suvorexant was also rejected earlier in 2013. What does this most recent rejection mean for investors, and is Merck making the right changes to its research and development structure? In the following video, a segment from The Motley Fool's health care show Market Checkup, analysts Max Macaluso and David Williamson discuss the impact of the FDA's decision.

Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$88.44 (1.18%) $1.03
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$65.25 (-1.19%) $0.79
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.64 (0.90%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.